| Title |
Immunotherapeutic Approaches to Biliary Cancer
|
|---|---|
| Published in |
Current Treatment Options in Oncology, June 2017
|
| DOI | 10.1007/s11864-017-0486-9 |
| Pubmed ID | |
| Authors |
Urvi A. Shah, Amara G. Nandikolla, Lakshmi Rajdev |
| Abstract |
Biliary tract cancers (BTCs) are rare aggressive neoplasms with a poor prognosis and a median survival of less than 1 year in the locally advanced or metastatic setting. Among the few patients who undergo curative resection the recurrence rates are high. About 90% of patients are detected at advanced stages, and systemic chemotherapy is the mainstay of their treatment. The treatment options for these patients are limited and multiple modalities of therapy from targeted therapy to immunotherapy and combination therapies (immunotherapy, targeted therapy, and chemotherapy) have been tested in this disease. Targeted therapies have failed to show a survival benefit. The deregulation of the immune system plays a significant role in the pathogenesis of BTCs. Therefore, immunotherapy, especially, immune checkpoint inhibitors hold great promise for this group of cancers. Numerous trials of immunotherapy in BTC are currently ongoing. In this review, we will discuss the available data and evidence for immunotherapy in BTC. |
Mendeley readers
The data shown below were compiled from readership statistics for 15 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 15 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 2 | 13% |
| Student > Bachelor | 2 | 13% |
| Researcher | 2 | 13% |
| Professor | 1 | 7% |
| Unspecified | 1 | 7% |
| Other | 2 | 13% |
| Unknown | 5 | 33% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 5 | 33% |
| Biochemistry, Genetics and Molecular Biology | 2 | 13% |
| Immunology and Microbiology | 1 | 7% |
| Unspecified | 1 | 7% |
| Unknown | 6 | 40% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 July 2017.
All research outputs
#20,433,667
of 22,986,950 outputs
Outputs from Current Treatment Options in Oncology
#560
of 672 outputs
Outputs of similar age
#275,129
of 315,513 outputs
Outputs of similar age from Current Treatment Options in Oncology
#12
of 13 outputs
Altmetric has tracked 22,986,950 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 672 research outputs from this source. They receive a mean Attention Score of 3.2. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 315,513 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.